Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from HUM

If You Invested $100 In Humana 10 Years Ago, Here's How Much You Would Have Today

Humana (NYSE:HUM) has outperformed the market over the past 10 years by 5.55% on an annualized basis producing an average annual return of 18.03%. Currently, Humana has a market capitalization of $59.08 billion.

UBS Upgrades Rating to Buy for Humana, Raises Price Target To $520

UBS Upgrades Rating to Buy for Humana, Raises Price Target To $520

UBS upgraded its rating of Humana (NYSE:HUM) to Buy with a price target of $520.00, changing its price target from $486.00 to $520.00. Shares of Humana are trading up 2.2% over the last 24 hours, at $458.92 per share. A move to $520.00 would account for a 13.31% increase from…

This Favorable Sign Appears On Humana's Chart

This Favorable Sign Appears On Humana's Chart

If history is any guide, there may be good fortune ahead for shares of Humana (NYSE:HUM). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Here's How Much You Would Have Made Owning Humana Stock In The Last 5 Years

Humana (NYSE:HUM) has outperformed the market over the past 5 years by 1.74% on an annualized basis producing an average annual return of 15.84%. Currently, Humana has a market capitalization of $55.72 billion.

5 Undervalued Insurance Stocks to Buy Right Now

Inflation has surged to multi-year highs, so the Fed is contemplating raising interest rates aggressively this year. And an increasing interest rate environment typically translates to revenue growth for financial companies, including insurers. Thus, we think it could be wise to bet on quality insurance stocks Cigna (CI), Humana (HUM),…

If You Invested $100 In This Stock 10 Years Ago, Here's How Much You Would Have Today

Humana (NYSE:HUM) has outperformed the market over the past 10 years by 5.66% on an annualized basis.

Forget Clover, Buy These 4 Healthcare Plan Stocks Instead

The pandemic-driven increase in health awareness and rising chronic diseases should drive the healthcare-plans industry’s growth. However, not all industry participants are well-positioned to gain in the near term. Clover Health (CLOV), with inconsistent financials and growth, is not expected to perform well. Therefore, fundamentally sound stocks in this space—UnitedHealth…

inkl

Read news from The Economist, FT, and more,
with one subscription

Better Buy for 2022: Humana vs. Clover Health

Better Buy for 2022: Humana vs. Clover Health

The rising aging population and the increasing spending on healthcare have been driving the health insurance industry’s growth. So, Humana (HUM) and Clover (CLOV) should benefit. But which of these two stocks is a better buy now? Read more to find out.

Expert Ratings For Humana

Expert Ratings For Humana

Analysts have provided the following ratings for Humana (NYSE:HUM) within the last quarter:

Humana Q4 Bottom-Line Beats Expectations, Plans Cost Savings

Humana Q4 Bottom-Line Beats Expectations, Plans Cost Savings

Humana Inc (NYSE: HUM) posts

Humana: Q4 Earnings Insights

Humana: Q4 Earnings Insights

Humana (NYSE:HUM) reported its Q4 earnings results on Wednesday, February 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Humana Earnings Preview

Humana Earnings Preview

Humana (NYSE:HUM) is set to give its latest quarterly earnings report on Wednesday, 2022-02-02. Here's what investors need to know before the announcement. Analysts estimate that Humana will likely report an Earnings Per Share (EPS) of $1.16.

Death Cross Looms Over Humana Investors

Death Cross Looms Over Humana Investors

If history is any guide, there may be trouble ahead for shares of Humana (NYSE:HUM). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

1 2 3 4 5

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Medicare Advantage

Cigna Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

388,966 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play